Onchilles Pharma Announces Presentation of Data for N17350 Program at SITC 2023

2023-09-27

免疫疗法临床研究AACR会议

SAN DIEGO--(BUSINESS WIRE)-- Onchilles Pharma, a private biotech company developing new pan-cancer therapeutics that leverage a novel mechanism of action, announced today the presentation of preclinical data for the N17350 program at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, to be held virtually and at the San Diego Convention Center from November 1-5, 2023. N17350, is a first-in-class biologic therapeutic inspired by the immunobiology of neutrophils, with the potential to be effective against a wide range of cancer types. The company is targeting to start first-in-human clinical trials in skin cancers, head and neck cancer, and triple-negative breast cancer in 2024. Presentation Details Poster Title: N17350 combines selective cancer killing with adaptive immune activation to eradicate tumors Abstract Number: 1344 Date and Time: Saturday, November 4, 9:00 a.m. to 8:30 p.m. PT Location: San Diego Convention Center, Hall A and B1 or online at About N17350 and its Novel Mechanism of Action First described in research published in Cell from the lab of Onchilles’ Co-Founder Lev Becker, human neutrophils release catalytically active neutrophil elastase (called ELANE), which selectively and potently kills cancer cells independent of their genetics and anatomical origin, mobilizes adaptive immunity, and avoids resistance mechanisms. The team at Onchilles translated this ground-breaking discovery into a proprietary set of molecules, including N17350, with the potential to treat a wide variety of tumor types with an optimal efficacy and safety profile. About Onchilles Pharma Onchilles Pharma is a global drug discovery and development company that leverages novel innate immuno-biology to develop the next generation of pan-cancer therapies. These first-in-class therapeutics exploit a novel fundamental mechanism of action to treat cancer independent of its genetic background or anatomical origin. The company is developing a pipeline of first-in-class biologic drug candidates and plans to start first-in-human clinical trials for its first program, N17350, in 2024 in skin cancers, head and neck cancer and triple negative breast cancer. For more info, visit .

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构